S-allyl derivatives of 6-mercaptopurine are highly potent drugs against human B-CLL through synergism between 6-mercaptopurine and allicin

Leukemia Research

Volumn 36, Issue 12, 2012, Pages 1536-1540

  Miron, Talia ^a   Wilchek, Meir ^a   Shvidel, Lev ^b   Berrebi, Alain ^b   Arditti, Fabian D ^a,b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

Author keywords

6 Mercaptopurine; Allicin; Human B CLL in vivo model in mice; Induction of death in B CLL cells; Pro apoptotic; S allyl thio mercaptopurine

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; MERCAPTOPURINE; PRODRUG; S ALLYLTHIO 6 MERCAPTOPURINE; S ALLYLTHIO 6 MERCAPTOPURINE RIBOSIDE; THIOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MEMBRANE TRANSPORT; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

6-MERCAPTOPURINE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; B-LYMPHOCYTES; CELL MEMBRANE PERMEABILITY; DISEASE MODELS, ANIMAL; DISULFIDES; DNA; DRUG SYNERGISM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, INBRED ICR; OXIDATION-REDUCTION; PRODRUGS; SULFHYDRYL COMPOUNDS; SULFINIC ACIDS;

EID: 84868210927     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.023     Document Type: Article

References (23)

1. Hirsch K., Danilenko M., Giat J., Miron T., Rabinkov A., Wilchek M., et al. Effect of purified allicin, the major ingredient of freshly crushed garlic, on cancer cell proliferation. Nutr Cancer 2000, 38:245-254.
2. Miron T., Mironchik M., Mirelman D., Wilchek M., Rabinkov A. Inhibition of tumor growth by a novel approach: in situ allicin generation using targeted alliinase delivery. Mol Cancer Ther 2003, 2:1295-1301.
3. Arditti F., Rabinkov A., Miron T., Reisner Y., Berrebi A., Wilchek M., et al. Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate. Mol Cancer Ther 2005, 4:325-331.
4. Sun L., Wang X. Effects of allicin on both telomerase activity and apoptosis in gastric cancer SGC-7901 cells. World J Gastroenterol 2003, 9:1930-1934.
5. Miron T., Wilchek M., Sharp A., Nakagawa Y., Naoi M., Nozawa Y., et al. Allicin inhibits cell growth and induces apoptosis through the mitochondrial pathway in HL60 and U937 cells. J Nutr Biochem 2008, 19:524-535.
6. Lachmann G., Lorenz D., Radeck W., Steiper M. The pharmacokinetics of the S35 labeled garlic constituents alliin, allicin and vinyldithiine. Arzneimittelforschung 1994, 44:734-743.
7. Freeman F., Kodera Y. Garlic chemistry - stability of S-(2-propenyl) 2-propene-1-sulfinothioate (allicin) in blood, solvents, and simulated physiological fluids. J Agric Food Chem 1995, 43:2332-2338.
8. Miron T., Listowsky I., Wilchek M. Reaction mechanisms of allicin and allyl-mixed disulfides with proteins and small thiol molecules. Eur J Med Chem 2010, 45:1912-1918.
9. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992, 43:329-339.
10. Sahasranaman S., Howard D., Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008, 64:753-767.
11. Robak T. Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity. Curr Med Chem 2009, 16:2212-2234.
12. Swann P.F., Waters T.R., Moulton D.C., Xu Y.Z., Zheng Q., Edwards M., et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996, 273:1109-1111.
13. Derijks L.J.J., Gilissen L.P.L., Hooymas P.M., Hommes D.W. Thiopurines in inflammatory Bowel disease. Aliment Pharmacol Ther 2006, 24:715-729.
14. Miron T., Arditti F., Konstantinovski L., Rabinkov A., Mirelman D., Berrebi A., et al. Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines. Eur J Med Chem 2009, 44:541-550.
15. Friedman S., Blumberg R.S. Inflammatory Bowel disease. Harrison's principles of internal medicine 2008, McGraw Hill, (chapter 289). 17th ed. A.S. Fauci, E. Braunwald, D.L. Kasper, S.L. Hauser, D.L. Longo, J.L. Jameson, J. Loscalzo (Eds.).
16. Polifka J.E., Friedman J.M. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002, 65:240-261.
17. Ferraris A.M., Rolfo M., Mangerini R., Gaetani G.F. Increased glutathione in chronic lymphocytic leukemia lymphocytes. Am J Hematol 1994, 47:237-238.
18. Obrador E., Benlloch M., Pellicer J.A., Asensi M., Estrela J.M. Intertissue flow of glutathione (GSH) as a tumor growth-promoting mechanism: interleukin 6 induces GSH release from hepatocytes in metastatic B16 melanoma-bearing mice. J Biol Chem 2011, 286:15716-15727.
19. Silber R., Farber C.M., Papadopoulos E., Nevrla D., Liebes L., Bruck M., et al. Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood 1992, 80:2038-2043.
20. Trachootham D., Zhang H., Zhang W., Feng L., Du M., Zhou Y., et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 2008, 112:1912-1922.
21. Brown K.K., Hampton M.B. Biological targets of isothiocyanates. Biochem Biophys Acta 2011, 1810:888-894.
22. Crook T.R., Souhami R.L., Whyman G.D., McLean A.E. Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide. Cancer Res 1986, 46:5035-5038.
23. Hamilton T.C., Winker M.A., Louie K.G., Batist G., Behrens B.C., Tsuruo T., et al. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985, 34:2583-2586.